$10.68
0.37% yesterday
Nasdaq, Feb 21, 10:00 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$10.72
-0.43 3.86% 1M
-0.76 6.62% 6M
-1.11 9.38% YTD
-0.82 7.11% 1Y
+4.09 61.69% 3Y
+1.37 14.65% 5Y
+1.37 14.65% 10Y
Nasdaq, Closing price Thu, Feb 20 2025
+0.05 0.47%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $7.62b
Enterprise Value $2.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 29.91
P/S ratio (TTM) P/S ratio 78.11
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -20.84%
Revenue (TTM) Revenue $97.56m
EBIT (operating result TTM) EBIT $-1.11b
Free Cash Flow (TTM) Free Cash Flow $-779.48m
Cash position $5.15b
EPS (TTM) EPS $-0.14
P/E forward negative
P/S forward 53.90
EV/Sales forward 20.64
Short interest 7.84%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,815 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Roivant Sciences forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Roivant Sciences forecast:

Buy
89%
Hold
11%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
98 98
21% 21%
100%
- Direct Costs 16 16
52% 52%
17%
93 93
4% 4%
96%
- Selling and Administrative Expenses 656 656
10% 10%
673%
- Research and Development Expense 538 538
5% 5%
551%
-1,102 -1,102
8% 8%
-1,129%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1,113 -1,113
6% 6%
-1,140%
Net Profit -117 -117
103% 103%
-120%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
Seeking Alpha
12 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Positive
The Motley Fool
12 days ago
Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum.
Neutral
GlobeNewsWire
12 days ago
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of cale...
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website www.roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today